NewswireToday - /newswire/ -
London, United Kingdom, 2008/05/29 - Report Buyer has added a new report showing that during 2008, results of major phase II studies in asthma with two different interleukin-13 antagonistic antibodies are expected, and will be decisive for the validation of a hot target.
Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report showing that during 2008, results of major phase II studies in asthma with two different interleukin-13 antagonistic antibodies are expected, and will be decisive for the validation of a hot target.
“Interleukin-13 (IL-13) Antibodies” reports that asthma affects at least five% of the population and five to ten% of them suffer from severe asthma. It is treated with steroids and bronchodilators, but urgently needs novel therapies. Interleukin-13 is regarded to have a central role in the development of allergic asthma, mediating airway inflammation, obstruction and hyper-reactivity.
Authors of the report say IL-13 has attracted great interest as a target for injected or inhaled biologics, including antibodies, proteins, peptides, antisense and small interfering RNA (siRNA). They note that there are at least six clinical stage direct or indirect IL-13 antagonists in active development. All of them are pursuing asthma as the clinical lead indication. Further two companies are close to phase I.
The report shows that clinical information obtained so far from the various IL-13 antagonists indicates that neutralisation of the effects of IL-13 appears to be safe and well tolerated and shows signs of clinical activity in asthma. There are various approaches to neutralise the effects of IL-13: by directly binding to IL-13 and, thus preventing the cytokine to bind to its receptor and induce signalling; by blocking one of the two receptor subunits to which IL-13 binds (the IL-13 receptor alpha and the IL-4 receptor alpha which share a common subunit for binding of IL-13)
The report “Interleukin-13 (IL-13) Antibodies” compiles the individual profiles of 13 different molecules in development as direct or indirect antagonists of IL-13 in various clinical indications and provides a competitor analysis in the field.
“Interleukin-13 (IL-13) Antibodies” is available from Report Buyer. For more information, see website.
Report Buyer product ID: LME00014
About Report Buyer
Report Buyer is a UK-based independent online store supplying business information. The website now carries over 70,000 business information products, including market reports, studies, books and events. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.